Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia.

IF 2.2 4区 医学 Q3 HEMATOLOGY
Leukemia & Lymphoma Pub Date : 2022-02-01 Epub Date: 2021-10-22 DOI:10.1080/10428194.2021.1992621
Thulasi Raman Ramalingam, Selvaraj Mohanraj, Anurekha Muthu, Vikram Prabhakar, Balasubramaniam Ramakrishnan, Lakshman Vaidhyanathan, Jose Easow, Thirumalairaj Raja
{"title":"Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia.","authors":"Thulasi Raman Ramalingam,&nbsp;Selvaraj Mohanraj,&nbsp;Anurekha Muthu,&nbsp;Vikram Prabhakar,&nbsp;Balasubramaniam Ramakrishnan,&nbsp;Lakshman Vaidhyanathan,&nbsp;Jose Easow,&nbsp;Thirumalairaj Raja","doi":"10.1080/10428194.2021.1992621","DOIUrl":null,"url":null,"abstract":"<p><p>Immunophenotyping plays a major role and is essential for establishing the diagnosis of chronic lymphocytic leukemia (CLL). Though CLL has a characteristic phenotype, diagnosis may be challenging due to immunophenotypic overlap with other B cell non-Hodgkin's lymphomas (B-NHL). Markers like CD200, CD43, CD20 and CD45 were found valuable in CLL and we investigated their diagnostic efficiency and accuracy in 174 patients with leukemic B-NHL. On the integration of four markers by a scoring system, 96% (49/51) of CLL cases showed a score of 3 or 4 and 90% (36/40) of non-CLL cases had a score of 0 or 1. This scoring system for CLL diagnosis showed a sensitivity of 98.2% and 96% in the analytical cohort and validation cohort respectively, which was significantly higher than the classical Matutes score. Hence we strongly suggest considering the expression of CD200, CD20, CD43 and CD45 in the diagnosis of B-NHL cases.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"377-384"},"PeriodicalIF":2.2000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2021.1992621","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 5

Abstract

Immunophenotyping plays a major role and is essential for establishing the diagnosis of chronic lymphocytic leukemia (CLL). Though CLL has a characteristic phenotype, diagnosis may be challenging due to immunophenotypic overlap with other B cell non-Hodgkin's lymphomas (B-NHL). Markers like CD200, CD43, CD20 and CD45 were found valuable in CLL and we investigated their diagnostic efficiency and accuracy in 174 patients with leukemic B-NHL. On the integration of four markers by a scoring system, 96% (49/51) of CLL cases showed a score of 3 or 4 and 90% (36/40) of non-CLL cases had a score of 0 or 1. This scoring system for CLL diagnosis showed a sensitivity of 98.2% and 96% in the analytical cohort and validation cohort respectively, which was significantly higher than the classical Matutes score. Hence we strongly suggest considering the expression of CD200, CD20, CD43 and CD45 in the diagnosis of B-NHL cases.

CD20、CD200、CD43和CD45在慢性淋巴细胞白血病中的独立诊断价值。
免疫分型在慢性淋巴细胞白血病(CLL)的诊断中起着重要的作用。尽管CLL具有特征性表型,但由于与其他B细胞非霍奇金淋巴瘤(B- nhl)的免疫表型重叠,诊断可能具有挑战性。我们发现CD200、CD43、CD20和CD45等标志物在CLL中有价值,并对174例白血病B-NHL患者的诊断效率和准确性进行了研究。在四项指标综合评分系统中,96%(49/51)的CLL病例得分为3或4分,90%(36/40)的非CLL病例得分为0或1分。该评分系统对CLL诊断的敏感性在分析队列和验证队列中分别为98.2%和96%,显著高于经典的Matutes评分。因此,我们强烈建议在诊断B-NHL病例时考虑CD200、CD20、CD43和CD45的表达。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia & Lymphoma
Leukemia & Lymphoma 医学-血液学
CiteScore
4.10
自引率
3.80%
发文量
384
审稿时长
1.8 months
期刊介绍: Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信